Zoetis (ZTS)
(Delayed Data from NYSE)
$169.56 USD
+0.12 (0.07%)
Updated May 31, 2024 04:00 PM ET
After-Market: $169.64 +0.08 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$169.56 USD
+0.12 (0.07%)
Updated May 31, 2024 04:00 PM ET
After-Market: $169.64 +0.08 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum C VGM
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Top Stock Reports for Anheuser-Busch, Gilead & Canadian National
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Anheuser-Busch InBev (BUD), Gilead Sciences (GILD) and Canadian National Railway (CNI).
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Why Is Zoetis (ZTS) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Intel, Coca-Cola, Starbucks, Caterpillar and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Coca-Cola, Starbucks, Caterpillar and Zoetis
Top Analyst Reports for Intel, Coca-Cola & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Coca-Cola (KO) and Starbucks (SBUX).
JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Top Stock Reports for Tesla, Disney & PepsiCo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), The Walt Disney Company (DIS) and PepsiCo (PEP).
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.
Zoetis (ZTS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 34.85% and 13.88%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.
Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Coronavirus Woes Impact Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports second-quarter 2020 results.
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis (ZTS) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zoetis (ZTS) Up 13.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Top Research Reports for Amgen, BHP, Altria & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), BHP Group (BHP) and Altria Group (MO).
Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.
Zoetis (ZTS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 7.95% and 1.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide pipeline updates along with financial numbers for the first quarter in its impending earnings release.
Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.